Abstract:In the age of anti-vascular endothelial growth factor (VEGF) therapy, we are fortunate as clinicians to have three great options in the treatment of neovascular age-related macular degeneration (AMD). Yet we still face a dilemma, in that we lack a truly sustainable treatment strategy. For various reasons, as a group we cannot maintain a monthly injection regimen for patients and are giving far less, approximately half of that, be it bevacizumab, ranibizumab, or aflibercept (Holekamp et al, 2014). Unfortunately… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.